Journal of Clinical Oncology, Vol 13, 1726-1733, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Long-term survival after histologic transformation of low-grade follicular lymphoma

AR Yuen, OW Kamel, J Halpern and SJ Horning
Department of Medicine, Stanford University Medical Center, CA 94304, USA.

PURPOSE: To describe the course of patients following histologic transformation (HT) from low-grade follicular lymphoma to intermediate- or high-grade non-Hodgkin's lymphoma. PATIENTS AND METHODS: Patients were identified from data bases in the Division of Oncology and the Department of Surgical Pathology. HT was defined as the conversion of a follicular small cleaved-cell or follicular mixed small cleaved-cell and large-cell lymphoma to a diffuse large-cell, diffuse mixed small cleaved-cell and large-cell or any high-grade lymphoma. RESULTS: We analyzed the clinical course of 74 low-grade lymphoma patients with histologically proven transformation occurring from 1965 to 1988. The median time from diagnosis to HT was 66 months, and the median age at HT was 58 years. The median duration of survival after transformation was 22 months. Anatomic extent of disease at HT (limited v extensive, P = .01), prior chemotherapy (none v any, P = .01), and response to therapy (complete v partial or none, P = .005) at time of HT were identified as significant predictors of survival after HT in backward- selection Cox regression analysis. Thirty patients attained a complete response to therapy at HT. They had a median survival duration of 81 months after HT. CONCLUSION: A subset of patients with HT from low- grade follicular lymphoma to intermediate- or high-grade lymphoma enjoys relatively long-term survival. Patients with limited disease and no previous exposure to chemotherapy have the most favorable prognosis.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J. Gentles, A. A. Alizadeh, S.-I. Lee, J. H. Myklebust, C. M. Shachaf, B. Shahbaba, R. Levy, D. Koller, and S. K. Plevritis A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients Blood, October 8, 2009; 114(15): 3158 - 3166. [Abstract] [Full Text] [PDF]

				A. Noy, H. Schoder, M. Gonen, M. Weissler, K. Ertelt, C. Cohler, C. Portlock, P. Hamlin, and H. W. D. Yeung The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL) Ann. Onc., March 1, 2009; 20(3): 508 - 512. [Abstract] [Full Text] [PDF]

				A. J. Al-Tourah, K. K. Gill, M. Chhanabhai, P. J. Hoskins, R. J. Klasa, K. J. Savage, L. H. Sehn, T. N. Shenkier, R. D. Gascoyne, and J. M. Connors Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5165 - 5169. [Abstract] [Full Text] [PDF]

				M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF]

				J. W. Friedberg, P. Cohen, L. Chen, K. S. Robinson, A. Forero-Torres, A. S. La Casce, L. E. Fayad, A. Bessudo, E. S. Camacho, M. E. Williams, et al. Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study J. Clin. Oncol., January 10, 2008; 26(2): 204 - 210. [Abstract] [Full Text] [PDF]

				M. H.J. van Oers Rituximab maintenance therapy: a step forward in follicular lymphoma Haematologica, June 1, 2007; 92(6): 826 - 833. [Abstract] [Full Text] [PDF]

				G. A. Salles Clinical Features, Prognosis and Treatment of Follicular Lymphoma Hematology, January 1, 2007; 2007(1): 216 - 225. [Abstract] [Full Text] [PDF]

				R. Advani, S. A. Rosenberg, and S. J. Horning Stage I and II Follicular Non-Hodgkin's Lymphoma: Long-Term Follow-Up of No Initial Therapy J. Clin. Oncol., April 15, 2004; 22(8): 1454 - 1459. [Abstract] [Full Text] [PDF]

				P. Corradini, M. Ladetto, F. Zallio, M. Astolfi, E. Rizzo, S. Sametti, A. Cuttica, R. Rosato, L. Farina, M. Boccadoro, et al. Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes J. Clin. Oncol., April 15, 2004; 22(8): 1460 - 1468. [Abstract] [Full Text] [PDF]

				A.J. Davies, A.Z.S. Rohatiner, S. Howell, K.E. Britton, S.E. Owens, I.N. Micallef, D.P. Deakin, B.M. Carrington, J.A. Lawrance, S. Vinnicombe, et al. Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., April 15, 2004; 22(8): 1469 - 1479. [Abstract] [Full Text] [PDF]

				N. Goldschmidt, E. Libson, A. Bloom, G. Amir, and O. Paltiel Clinical utility of computed tomography-guided core needle biopsy in the diagnostic re-evaluation of patients with lymphoproliferative disorders and suspected disease progression Ann. Onc., September 1, 2003; 14(9): 1438 - 1441. [Abstract] [Full Text] [PDF]

				C. D. Williams, C. N. Harrison, T. A. Lister, A. J. Norton, A. K. Blystad, B. Coiffier, G. Taghipour, N. Schmitz, and A. H. Goldstone High-Dose Therapy and Autologous Stem-Cell Support for Chemosensitive Transformed Low-Grade Follicular Non-Hodgkin's Lymphoma: A Case-Matched Study From the European Bone Marrow Transplant Registry J. Clin. Oncol., February 1, 2001; 19(3): 727 - 735. [Abstract] [Full Text] [PDF]

				E. Diamandidou, M. Colome-Grimmer, L. Fayad, M. Duvic, and R. Kurzrock Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis Blood, August 15, 1998; 92(4): 1150 - 1159. [Abstract] [Full Text] [PDF]

				W. H. Wilson, J. Teruya-Feldstein, T. Fest, C. Harris, S. M. Steinberg, E. S. Jaffe, and M. Raffeld Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas Blood, January 15, 1997; 89(2): 601 - 609. [Abstract] [Full Text] [PDF]